Navigation Links
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
Date:6/26/2010

pan class="xn-money">$174 billion per year in direct and indirect medical expenses.(iv)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(v) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(vi) Data indicate that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vii,viii)

About BYETTA® (exenatide) injection

BYETTA is the first FDA-approved GLP-1 receptor agonist for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight-loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. See important safety information below.  Additional information about BYETTA is available at

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Depth charge: Using atomic force microscopy to study subsurface structures
2. Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study
3. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
4. Independent Study Reveals dabl System Leads the way in Accurate Cardiovascular Diagnosis
5. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
6. DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
7. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
8. Chiasma Reports Successful Oral Delivery Of A Peptide In Clinical Study
9. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
10. Two-Year Follow up Data of NuBac® IDE Feasibility Study Was Presented at SAS Meeting
11. Reaction Progress Kinetic Analysis to Study Organic Reactions: Free On-Demand Online Seminar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... international research team including DESY scientists has observed tiny ... team reports in the journal Science that ... inside the nanodroplets. It is the first time that ... larger samples of what is known as superfluid helium, ... our best expectations," says Andrey Vilesov of the University ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
(Date:8/21/2014)... Bulgaria (PRWEB) August 21, 2014 ... released today by Ontotext . Now the ... semantic analysis of structured and unstructured data is available ... the cost of enterprise technology. Organizations that do not ... for data management can use S4 since there is ...
Breaking Biology Technology:Scientists observe quantum vortices in cold helium droplets 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... , BETHESDA, Md., Sept. 21 ... company developing novel, proprietary antibodies for the treatment of cancer, ... a phase 1 dose-escalation clinical study for BiTE antibody MT110, ... tumors. The interim data(1) were presented at the Multidisciplinary ...
... , , , ... 21 Volcano Corporation (Nasdaq: VOLC ), a leader ... and treatment of coronary and peripheral artery disease, announced today its ... Francisco, CA from September 21-25. Volcano programming for TCT includes a ...
... ST. PAUL, Minn., Sept. 21 Brennen Medical, LLC, ... device to Davol Inc., a subsidiary of C.R. Bard, Inc. ... of the hernia products business of Brennen Medical, LLC. This ... in soft tissue repair including hernia and abdominal wall reconstruction. , ...
Cached Biology Technology:Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 2Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 3Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 2Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 3Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 4Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 5Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference 6Brennen Medical Announces Sale of XenMatrix(R) 2
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
(Date:8/21/2014)... itself resulting in severe abdominal pain, vomiting and systemic ... are diagnosed with the disease resulting in 1000 deaths. ... to intravenous fluid and nutritional support. , Dr ... led the research, said "The major causes of pancreatitis ... alcohol intake combined with a high fat diet. In ...
(Date:8/20/2014)... a study of 158 pregnant teenagers in Rochester, NY, ... intentional consumption of ice, cornstarch, vacuum dust, baby powder ... Cornell study. , Moreover, such teens had significantly lower ... eat nonfood substances. , Pregnant teens, regardless of pica, ... lead to iron deficiency and anemia. Low iron in ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2
... the behaviors of individual cells and the functions and ... the complex interactions of cell clusters have not been ... Emergent Behaviors of Integrated Cellular Systems (EBICS) Center to ... the University of Illinois at Urbana-Champaign, and the Georgia ...
... From how massive humpbacks glide through the sea with ease ... Harvard have excavated the equations behind a variety of complex ... Michael Brenner, working closely with a team of Harvard evolutionary ... most famous icon of evolution: the beaks of Darwin,s finches. ...
... industrialized countries have easy access to healthy food and nutritional ... because new research from Tel Aviv University suggests that magnesium, ... even more critical than previously thought for the neurons of ... MIT, the research started as a part of a post-doctoral ...
Cached Biology News:$25M NSF center established to investigate the creation of biological machines 2$25M NSF center established to investigate the creation of biological machines 3$25M NSF center established to investigate the creation of biological machines 4Simple math explains dramatic beak shape variation in Darwin's finches 2Simple math explains dramatic beak shape variation in Darwin's finches 3Remember magnesium if you want to remember 2
Mouse Activin RIB/ALK-4 MAb (Clone 207304)...
Normal human serum, single donor...
... SYBR Green, TaqMan, LNA spiked TaqMan, MethyLight, ... specific primers are designed by avoiding cross ... results. Primer efficiency is enhanced by avoiding ... the Mfold server. Beacon Designer can be ...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: